It can significantly reduce the behaviour of cancer stem cells in vivo and in vitro models by utilising FDA-approved selective small molecule inhibitors to target JAK or STAT1, offering patients additional therapeutic choices [113]. This evidence concerns the gene STAT1 and cancer.